Scientists Who Cracked the Genetic Key to Sickle Cell Disease Win 2026 Breakthrough Prize in Life Sciences

Two researchers whose fundamental discoveries about hemoglobin biology laid the scientific groundwork for the world's first FDA-approved gene-editing therapy won the 2026 Breakthrough Prize in Life Sciences, honored at a ceremony in Santa Monica, California on Saturday night. Stuart H. Orkin of Harvard Medical School and Boston Children's Hospital and Swee Lay Thein of the National Heart, Lung and Blood Institute shared the $3 million prize for their work identifying the molecular switch that controls the transition from fetal to adult hemoglobin — a discovery that opened an entirely new therapeutic avenue for treating sickle cell disease and beta-thalassemia, conditions that together affect tens of millions of people globally.

Sickle cell disease is a genetic disorder affecting approximately 100,000 Americans and millions more worldwide, predominantly in populations of African, Mediterranean, Middle Eastern, and Indian descent. It arises from a single mutation in the gene for adult beta-globin, causing red blood cells to take on a rigid, crescent shape that obstructs blood flow, triggering agonizing pain crises, organ damage, and shortened lifespans. For most of the twentieth century, treatment options were limited to managing symptoms or, in rare cases, bone marrow transplantation available only to patients with matched donors. The disease's disproportionate impact on Black patients and communities with limited access to specialty care meant that investment in better treatments lagged behind comparable genetic disorders for decades.

Thein, a clinician-scientist originally from Myanmar who built her career at King's College London before joining the NIH, identified the genetic variants that determine why some adults continue producing fetal hemoglobin — the form of hemoglobin present before birth, which is not susceptible to sickling — long after the normal developmental switch would turn it off. Her work revealed that individuals who naturally retain high fetal hemoglobin levels experience milder disease, suggesting that pharmacologically reactivating the switch could be therapeutic. Orkin's laboratory subsequently identified BCL11A, the master transcription factor that normally represses fetal hemoglobin production after birth. His team showed that disrupting BCL11A in blood stem cells could reactivate fetal hemoglobin production to clinically meaningful levels without harming the cells.

Those discoveries became the direct scientific basis for Casgevy, the CRISPR-Cas9-based therapy developed by CRISPR Therapeutics and Vertex Pharmaceuticals that received FDA approval in December 2023 — the first gene-editing treatment ever approved for any disease. Casgevy works by precisely disrupting BCL11A enhancer sequences in a patient's own extracted blood stem cells, permanently reactivating fetal hemoglobin production before the modified cells are reinfused. In clinical trials, 97 percent of patients who received the one-time treatment went at least 12 months without a severe vaso-occlusive crisis. Accepting the prize, Orkin said: "At a time when people are questioning the value of science, this is a good example" of what decades of curiosity-driven basic research can achieve.

The same Breakthrough Prize round recognized two additional teams in life sciences: Jean Bennett, Katherine A. High, and Albert Maguire of the University of Pennsylvania, whose pioneering work led to the first FDA-approved gene therapy for inherited blindness; and Rosa Rademakers and Bryan Traynor, who identified the C9orf72 mutation as the most common genetic cause of both ALS and frontotemporal dementia, opening new therapeutic targets. Together, the prizes reflected a broader scientific moment in which decades of basic genetic research are yielding approved treatments with the potential to cure previously untreatable inherited diseases — and a rebuke to those who argue that fundamental science cannot justify its cost.